XML 141 R55.htm IDEA: XBRL DOCUMENT
v3.20.1

Equity-Accounted Investees (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Accounted investees with similar activity to that of the Group |
Equity Accounted Investees |
Schedule of details of equity accounted investees |
|  |  |  | Thousands of |  |  |  | Thousands of
|  |  |  | Euros |  |  |  | Euros
|  | % ownership |  | 31/12/2019 |  | % ownership |  | 31/12/2018
Interstate Blood Bank, Inc. |  | 100.00 | % | — |  | 49.19 | % | 29,595
Bio Blood Components Inc. |  | 0.00 | % | — |  | 48.97 | % | 38,223
Plasma Biological Services, LLC |  | 0.00 | % | — |  | 48.90 | % | 21,809
Access Biologicals LLC |  | 49.00 | % | 49,922 |  | 49.00 | % | 47,742
Plasmavita HealthCare |  | 50.00 | % | 10,368 |  | 50.00 | % | 9,920
|  |  |  | 60,290 |  |  |  | 147,289
Schedule of movement in investments in equity-accounted investees |
|  | Thousands of Euros
|  | 2019
Balance at 1 January |  | —
Transfer accounted investees with similar activity to that of the Group |  | 147,289
Transfers |  | (94,127)
Share of profit / (losses) |  | 8,972
Share of other comprehensive income / translation differences |  | 2,624
Losses for Impairment |  | —
Collected dividends |  | (4,468)
Balance at 31 December |  | 60,290
Access Biologicals LLC |
Equity Accounted Investees |
Schedule of movement in investments in equity-accounted investees |
|  | Thousand of Euros
|  | 31/12/2019 |  | 31/12/2018
Balance at 1 January |  | 47,742 |  | 44,219
Acquisitions |  | — |  | —
Share of profit / (losses) |  | 3,938 |  | 3,039
Share of other comprehensive income / translation differences |  | 967 |  | 2,073
Collected dividends |  | (2,725) |  | (1,589)
Balance at 31 December |  | 49,922 |  | 47,742
Interstated Blood Bank, Inc. Group |
Equity Accounted Investees |
Schedule of movement in investments in equity-accounted investees |
|  | Thousands of Euros |  | Thousands of Euros |  |  |  |
|  | 31/12/2019 |  | 31/12/2018 |  |  |  |
|  | IBBI |  | Bio-Blood |  | PBS |  | IBBI |  | Bio-Blood |  | PBS |  | TOTAL 2019 |  | TOTAL 2018
Balance at 1 January |  | 29,595 |  | 38,223 |  | 21,809 |  | 27,936 |  | 32,960 |  | 23,010 |  | 89,627 |  | 83,906
Transfers |  | (31,453) |  | (38,606) |  | (24,068) |  | — |  | — |  | — |  | (94,127) |  | —
Share of profit / (losses) |  | 6,853 |  | (2,543) |  | 276 |  | 1,830 |  | 3,492 |  | (2,181) |  | 4,586 |  | 3,141
Share of other comprehensive income / translation differences |  | (3,251) |  | 2,926 |  | 1,983 |  | 1,298 |  | 1,771 |  | 980 |  | 1,658 |  | 4,049
Collected dividend |  | (1,744) |  | — |  | — |  | (1,469) |  | — |  | — |  | (1,744) |  | (1,469)
Balance at 31 December |  | — |  | — |  | — |  | 29,595 |  | 38,223 |  | 21,809 |  | — |  | 89,627
Rest of equity accounted investees |
Equity Accounted Investees |
Schedule of details of equity accounted investees |
|  |  |  | Thousands of Euros |  |  |  | Thousands of Euros
|  | % ownership |  | 31/12/2019 |  | % ownership |  | 31/12/2018
Alkahest, Inc. |  | 47.58 | % | 14,708 |  | 47.58 | % | 28,336
Albajuna Therapeutics, S.L |  | 49.00 | % | 5,228 |  | 30.00 | % | 1,106
Singulex, Inc. |  | 0.00 | % | — |  | 19.33 | % | 19,256
GigaGen, Inc |  | 43.96 | % | 23,997 |  | 43.96 | % | 28,363
Mecwins, S.A. |  | 24.99 | % | 2,338 |  | 24.99 | % | 2,555
Medcom Advance, S.A |  | 45.00 | % | 7,912 |  | — |  | —
|  |  |  | 54,183 |  |  |  | 79,616
Schedule of movement in investments in equity-accounted investees |
|  | Thousands of Euros
|  | 2019 |  | 2018 |  | 2017
Balance at 1 January |  | 79,616 |  | 219,009 |  | 201,345
Acquisitions |  | 12,369 |  | 12,222 |  | 80,685
Transfers |  | — |  | 500 |  | (16,000)
Share of profit / (losses) |  | (19,744) |  | (11,038) |  | (13,195)
Share of other comprehensive income / translation differences |  | 1,736 |  | 9,270 |  | (27,134)
Losses for Impairment |  | (19,794) |  | — |  | (6,692)
Collected dividends |  | — |  | (3,058) |  | —
Balance at 31 December |  | 54,183 |  | 226,905 |  | 219,009
GigaGen, Inc |
Equity Accounted Investees |
Schedule of movement in investments in equity-accounted investees |
|  | Thousand of Euros
|  | 31/12/2019 |  | 31/12/2018
Balance at 1 January |  | 28,363 |  | 29,047
Acquisitions |  | — |  | —
Share of profit / (losses) |  | (5,002) |  | (1,562)
Share of other comprehensive income / translation differences |  | 636 |  | 878
Balance at 31 December |  | 23,997 |  | 28,363
Singulex, Inc. |
Equity Accounted Investees |
Schedule of movement in investments in equity-accounted investees |
|  | Thousand of Euros
|  | 31/12/2019 |  | 31/12/2018
Balance at 1 January |  | 19,256 |  | 29,322
Share of profit / (losses) |  | — |  | (10,975)
Share of other comprehensive income / translation differences |  | 538 |  | 909
Losses for Impairment |  | (19,794) |  | —
Balance at 31 December |  | — |  | 19,256

X
- Definition The disclosure of the reconciliation of changes in investments accounted for using the equity method. + References No definition available. + Details
Name: | grfs_DisclosureOfReconciliationOfChangesInInvestmentsAccountedForUsingEquityMethodTableTextBlock
Namespace Prefix: | grfs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_10_e&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=grfs_EquityAccountedInvesteesGroupOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=grfs_AccessBiologicalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=grfs_InterstatedBloodBankInc.GroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=grfs_EquityAccountedInvesteesGroupTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=grfs_GigagenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=grfs_SingulexIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |